These 3 Companies are Seeing Supercharged Sales Growth

The 2025 Q2 earnings season concluded with largely positive and resilient results, indicating an optimistic outlook for Q3. Eli Lilly (LLY) posted strong Q2 sales of $15.5 billion, up 38% year-over-year, driven by Zepbound and Mounjaro, leading to increased FY25 guidance. Interactive Brokers (IBKR) demonstrated robust platform growth with customer accounts surging 32% and commission revenue up 27% year-over-year due to heightened trading volumes. Eaton (ETN) also achieved a record Q2 with adjusted EPS of $2.95 and 8% organic sales growth, benefiting significantly from AI-related data center demand.

Analysis

The Q2 2025 earnings season demonstrated broad resilience with positive revisions for Q3, setting a constructive market backdrop. Within this environment, several firms showed exceptional fundamental strength. Eli Lilly (LLY) reported a 38% year-over-year increase in sales to $15.5 billion, beating consensus estimates by 6%, propelled by massive volume growth in Zepbound (+172%) and Mounjaro (+68%). Despite its stock underperforming year-to-date (-5%), the company's raised FY25 revenue and EPS guidance, coupled with gross margin expansion to 84.3% and positive analyst revisions, underscore its operational momentum. In the financial technology sector, Interactive Brokers (IBKR) has seen its stock surge nearly 110% over the past year, supported by robust platform growth that includes a 32% YoY increase in customer accounts to 3.9 million and a 27% rise in commission revenue. This growth is directly tied to significant increases in trading volumes across stocks, options, and futures. Meanwhile, Eaton (ETN) capitalized on the AI infrastructure build-out, delivering a record-breaking quarter with adjusted EPS of $2.95 (+8% YoY) and record segment margins of 23.9%, driven by accelerating orders for its power management solutions in the data center market. ETN also maintains a strong appeal for income-focused investors with a 7.5% five-year annualized dividend growth rate and a payout history stretching back to 1923.

Key Decisions for Investors

• For Eli Lilly, the divergence between its 5% year-to-date stock decline and its fundamental strength—highlighted by 38% revenue growth and raised FY25 guidance—may signal a strategic entry point, reinforced by positive analyst revisions and reported insider buying.
• Interactive Brokers' 110% stock appreciation over the past year, fueled by 32% customer growth and strong trading volumes, warrants a review of its current valuation to determine if the robust performance is fully priced in.
• Eaton's record Q2 performance, driven by AI-related data center demand, positions it as a compelling investment for exposure to the AI theme, offering a blend of growth from its 8% organic sales increase and reliable income via its historically consistent and growing dividend.